Share this NATF page   

April 2014


President's Letter

I’ve just returned from the annual American College of Cardiology (ACC) Scientific Symposium in Washington, D.C. Multiple members of NATF’s Board of Directors and Scientific Advisory Committee presented talks and participated in scientific debates covering a variety of thrombotic diseases: pulmonary embolism, deep vein thrombosis, stroke, and myocardial infarction. The meeting was informative and innovative. Now the challenge lies in connecting the medical findings and ACC consensus opinions with the points of view of patients, their families, and the public.

Click here to read the full President's Letter.

NATF Update

SEATTLE-II: A New Era for Massive and Submassive PE


NATF Education Chair and Board Member, Dr. Gregory Piazza, joins NATF President, Dr. Samuel Z. Goldhaber on "The Clot Blog, to discuss the SEATTLE-II Trial.  Watch the full interview!


NATF Assumes Management of the DVT Coalition

Screen Shot 2014-02-26 At 4.05.06 PMIn February 2003, more than 70 organizations assembled at the Public Health Leadership Conference on Deep-Vein Thrombosis (DVT) in Washington, D.C. to discuss the urgent need to make DVT a major U.S. public health priority. As a result of this meeting, which was co-hosted by the American Public Health Association (APHA) and Centers for Disease Control and Prevention (CDC) and funded by Sanofi-Aventis, participants agreed to establish a Coalition of organizations committed to educating the public and healthcare community about DVT.

Read more about the NATF and DVT Coalition merge here.

Educational Programs

NATF Summit Highlights

Gregory Piazza, MD, MS, gives commentary on two lectures from the NATF Summit: VTE and Cancer, and Heart Failure and Thrombosis. Watch below!


Online CME Program

Program Chairs Samuel Z. Goldhaber, MD, and Christian Ruff, MD, of Harvard Medical School, lead an international faculty of thrombosis experts as they gather together to analyze the latest landmark trials—ENGAGE AG-TIMI 48 and Hokusai-VTE—evaluating edoxaban for SPAF and the treatment of acute VTE.

Image 001

News and Articles

ACC/AHA cardiovascular risk equations get a thumbs-up

Family Practice News
: 14 April 2014 - The controversial cardiovascular risk estimator introduced in the current ACC/AHA risk-assessment guidelines demonstrated "moderate to good" predictive performance...

Read the full article here.

Mayo Clinic gets $39.5M grant to fund stroke study

Brain -Memory -Health -Stroke -Medical -Caduceus -jpgNewsforJax: 16 April 2014 - Is medicine as safe and effective as surgery or stenting in preventing a stroke caused by the buildup of plaque in the carotid artery? Thomas G. Brott, M.D., a neurologist at Mayo Clinic in Florida, aims to find out.

Read the article here.

FDA approves Pradaxa for treatment of deep venous thrombosis and pulmonary embolism

Pradaxa 14 April 2014 - Boehringer Ingelheim Pharmaceuticals announced that the US Food and Drug Administration (FDA) has approved Pradaxa (dabigatran etexilate mesylate) for the treatment of deep venous thrombosis and pulmonary embolism in patients who have been treated with a parenteral anticoagulant for five to 10 days...

Read the article here.

About NATF





Giving to NATF

North American Thrombosis Forum
368 Boylston Street
Brookline, MA 02445

617 - 730 - 4120

NATF is a 501(c) nonprofit

Contact Us

© 2012 North American Thrombosis Forum

Web Development by MTC